Could an asthma drug stop High-Altitude lung swelling?
NCT ID NCT06040268
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether the asthma inhaler Advair HFA can prevent high altitude pulmonary edema (HAPE), a dangerous buildup of fluid in the lungs at high altitudes. Researchers will give the drug or a placebo to 60 healthy volunteers and people prone to HAPE, then measure their exercise performance and lung function under simulated high-altitude conditions. The goal is to see if the drug is safe and can improve oxygen levels and exercise capacity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Advair HFA (salmeterol and fluticasone inhaler)
- What this could lead to
- If it works, this could point toward a way to prevent dangerous fluid buildup in the lungs at high altitudes for susceptible people.
- What could go wrong
- This is an early phase trial with only 60 participants, so results may not apply broadly. The drug also has known side effects like increased heart rate or throat irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALTITUDE EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.